Sarah Gheuens - Oct 30, 2025 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Signature
/s/ William Cook, as attorney-in-fact for Sarah Gheuens
Stock symbol
AGIO
Transactions as of
Oct 30, 2025
Transactions value $
-$3,760
Form type
4
Date filed
11/3/2025, 04:10 PM
Previous filing
Oct 29, 2025
Next filing
Nov 13, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gheuens Sarah Chief Medical Officer 88 SIDNEY STREET, CAMBRIDGE /s/ William Cook, as attorney-in-fact for Sarah Gheuens 2025-11-03 0001881190

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGIO Common stock Options Exercise $5K +200 +0.32% $25.01 61.9K Oct 30, 2025 Direct
transaction AGIO Common stock Sale -$8.76K -200 -0.32% $43.81 61.7K Oct 30, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Stock options (right to buy) Options Exercise $0 -200 -0.69% $0.00 28.6K Oct 30, 2025 Common stock 200 $25.01 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.